Previous 10 | Next 10 |
2023-11-30 11:00:00 ET Summary The weight loss drug, Zepbound, faces immense competition and may lose its battle once a pill form of weight loss drug becomes available. The company has a surprisingly low diversification of revenues. Revenues are susceptible to upcoming LOEs. T...
2023-11-30 05:26:00 ET It's been a great run, but Ozempic's spotlight could begin fading fast. New research strongly suggests a competing diabetes treatment from Eli Lilly (NYSE: LLY) is even better at helping patients manage their weight than the leading brand. Recently, resear...
2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...
2023-11-29 10:45:34 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – November 29, 2023 – USA News Group – According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the ri...
2023-11-28 20:25:05 ET Eli Lilly and Company (LLY) 6th Evercore ISI HealthCONx Conference November 28, 2023 03:50 PM ET Company Participants Dan Skovronsky - EVP, Chief Scientific and Medical Officer Conference Call Participants Umer Raffat - Evercore ISI ...
2023-11-28 16:08:20 ET More on Verve Therapeutics Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve falls after early-stage data for lead asset Verve shares surge to thr...
2023-11-28 09:03:00 ET U.S. stock index futures on Tuesday pointed to a marginally lower open. Market participants looked forward to housing and consumer data along with a $39B 7-year note auction. Here are some stocks to watch on Tuesday: For further details see: 4 stocks to wa...
2023-11-28 08:17:10 ET More on Eli Lilly Eli Lilly: Perfectly Priced Healthcare Giant Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript) M&A, ...
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego PR Newswire Alexandria and Lilly, which began their strategic relationship in 2008, are collaborating to support and accelerate the development of pro...
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego PR Newswire Scheduled to open in the first half of 2024, Lilly's new Gateway Labs location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facilit...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 07:07:00 ET If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the...
2024-07-30 05:48:00 ET Going into 2024, DexCom 's (NASDAQ: DXCM) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes. However, last week was the worst for De...
2024-07-29 15:13:21 ET Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding th...